Catalent Inc (0C8.SG)
| Previous close | 51.45 |
| Open | 53.00 |
| Bid | 0.00 x 300000 |
| Ask | 0.00 x 300000 |
| Day's range | 53.00 - 61.87 |
| 52-week range | 39.41 - 112.06 |
| Volume | |
| Avg. volume | 3 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Catalent, Inc. Announces Second Quarter Fiscal Year 2023 Earnings Conference Webcast
SOMERSET, N.J., January 20, 2023--Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that it will release financial results for the second quarter of fiscal year 2023 ended December 31, 2022, before the market open on Tuesday, February 7, 2023. The Company’s management will host a webcast to discuss the results at 8:15 a.m. ET
- Business Wire
Catalent Appoints Ricardo Zayas as North American Biologics Operations Leader
SOMERSET, N.J., January 17, 2023--Catalent Appoints Ricardo Zayas as North American Biologics Operations Leader
- PR Newswire
Avantor® and Catalent Enter into Multi-Year Supply and Services Agreement
Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, today announced that it has entered into a multi-year supply and services agreement with Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide. Under the terms of the agreement, Avantor will be the primary supplier of a broad range of laborator
